Deep Track Capital
Deep Track Capital is an investment firm focused exclusively on the life sciences industry.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Deep Track Capital Information
Geographic Data
Address: 200 Greenwich Avenue
City: Greenwich
State: CT
Zip: 06830
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Deep Track Capital is an investment firm focused exclusively on the life sciences industry.
Contact Phone:
+12034090810
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2023 | Hemab | Series B | 0 |
| 12/2022 | Apogee Therapeutics | Series B | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 9/2022 | Valneva | Post-IPO Equity | 100.9M |
| 9/2021 | Obsidian Therapeutics | Series B | 0 |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 5/2023 | Carmot Therapeutics | Series E | 0 |
| 10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
| 1/2022 | Metagenomi | Series B | 0 |
| 8/2022 | Heron Therapeutics | Post-IPO Equity | 76.5M |
| 7/2022 | Carmot Therapeutics | Series D | 0 |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 9/2022 | Allakos | Post-IPO Equity | 0 |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 9/2022 | Abivax | Post-IPO Equity | 0 |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 8/2022 | ShouTi | Series B | 0 |
| 6/2021 | Anavex | Post-IPO Equity | 50M |
| 8/2022 | Structure Therapeutics | Series B | 0 |
| 7/2021 | Artios Pharma | Series C | 0 |
| 7/2019 | Frontier Medicines | Series B | 88.5M |
| 11/2021 | Tricida | Post-IPO Equity | 42M |
| 5/2021 | Magenta Therapeutics | Post-IPO Equity | 86.4M |
| 1/2022 | Third Harmonic Bio | Series B | 0 |
| 3/2023 | Orchard Therapeutics | Post-IPO Equity | 0 |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 8/2022 | Structure Therapeutics | Series B | 33M |
| 4/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 75M |
| 11/2022 | Lusaris Therapeutics | Series A | 0 |
| 10/2022 | Immunovant | Post-IPO Equity | 75M |
| 8/2022 | Structure Therapeutics | Series B | 0 |
| 8/2022 | ShouTi | Series B | 0 |
| 7/2022 | Carmot Therapeutics | Series D | 0 |
| 1/2022 | Metagenomi | Series B | 0 |
| 1/2022 | Third Harmonic Bio | Series B | 0 |
| 11/2021 | Tricida | Post-IPO Equity | 0 |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 9/2021 | Obsidian Therapeutics | Series B | 0 |
| 8/2021 | Dice Therapeutics | Series C | 0 |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
